Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment. (21st November 2022)

• Record Type: Journal Article
• Authors: Ammerman, Nicole C; Nuermberger, Eric L; Owen, Andrew; Rannard, Steve P; Meyers, Caren Freel; Swindells, Susan
• Is Part Of: Clinical infectious diseases. Volume 75(2022)Supplement 4
• Page Start: S510
• Page End: S516
• Publication Date: 2022-11-21
• Subjects: tuberculosis -- latent tuberculosis infection -- tuberculosis preventive treatment -- long-acting; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac672
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: A key component of global tuberculosis (TB) control is the treatment of latent TB infection. The use of long-acting technologies to administer TB preventive treatment has the potential to significantly improve the delivery and impact of this important public health intervention. For example, an ideal long-acting treatment could consist of a single dose that could be administered in the clinic (ie, a "1-shot cure" for latent TB). Interest in long-acting formulations for TB preventive therapy has gained considerable traction in recent years. This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of TB drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies. Abstract : This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of tuberculosis drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies.